Abbott Laboratories (ABT) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 adjusted EPS of approximately $1.15, up 5.5% from $1.09 in Q1 2025.
• Consensus revenue forecast stands at around $11.0 billion, reflecting about 6.5% growth year-over-year.
• Abbott's own guidance for Q1 adjusted EPS is $1.12 to $1.18, aligning closely with Wall Street views.
• Investors will watch medical devices and diagnostics for strength, amid nutrition segment pressures.
• The company has met or beaten EPS estimates in the last four quarters.
• Full-year 2026 guidance projects 6.5%-7.5% organic sales growth and adjusted EPS of $5.55-$5.80.

Earnings Context and Why It Matters

Abbott Laboratories (ABT), a global leader in medical devices, diagnostics, nutrition, and established pharmaceuticals, faces heightened scrutiny in its upcoming first-quarter 2026 earnings. Following a mixed Q4 2025 report—where adjusted EPS met expectations at $1.50 but revenue of $11.46 billion missed estimates due to nutrition weakness—the market seeks signs of recovery. Nutrition pricing adjustments continue to weigh on volumes, while strengths in continuous glucose monitoring (CGM) and structural heart devices drive optimism. For investors, this report offers insights into segment momentum, margin trends, and reaffirmed full-year guidance amid a competitive healthcare landscape. With ABT's stock down recently, clarity on execution could influence sentiment in a sector sensitive to innovation and demand shifts.

Earnings Expectations

Wall Street anticipates first-quarter 2026 adjusted earnings per share (EPS) of about $1.15, a 5.5% increase from $1.09 reported in the year-ago period. Consensus revenue estimates hover around $11.0 billion to $11.02 billion, implying roughly 6.5% growth compared to Q1 2025's $10.36 billion. This aligns with Abbott's guidance from its Q4 earnings call, projecting Q1 adjusted EPS between $1.12 and $1.18.

Key metrics in focus include medical devices, expected to lead growth via CGM sales like FreeStyle Libre, and diagnostics excluding COVID-19 testing. Nutrition remains challenged by promotional pricing to regain share, as flagged in prior results. Historically, Abbott has delivered EPS beats or meets in the last four quarters, though revenue has been softer. Stock reactions post-earnings have been mixed, with average moves reflecting guidance quality.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis of ABT and similar healthcare names.

Market Reaction and Investor Sentiment

Heading into Q1 earnings on April 16, sentiment around ABT is cautious but constructive. The stock has declined about 8% over the past month amid broader market pressures and lingering concerns over nutrition. Implied volatility suggests a potential 5-7% move post-report, consistent with historical patterns. Key risks include further nutrition softness or diagnostics slowdowns, while beats in devices could spark upside. Analysts maintain a "Moderate Buy" to "Strong Buy" consensus, with price targets averaging above current levels.

Forward Outlook and Key Factors to Monitor

Abbott's full-year 2026 guidance signals confidence, with organic sales growth targeted at 6.5%-7.5% and adjusted EPS of $5.55-$5.80, implying about 10% growth at the midpoint. This builds on Q4 2025 momentum in medical devices, where CGM and electrophysiology products like Volt PFA drove double-digit gains.

Post-earnings, watch nutrition recovery through new product launches and volume stabilization in the second half. Margin expansion—demonstrated by Q4's 150 basis-point operating margin improvement to 25.8%—remains a focus amid cost discipline.

Upcoming catalysts include the Exact Sciences acquisition closing in Q2, bolstering cancer diagnostics, and regulatory progress in structural heart and neuromodulation. Demand signals in emerging markets and U.S. device procedures will indicate sustained growth. Investors should track guidance updates for any shifts in nutrition or COVID-exited diagnostics trends.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.